Effect of roflumilast in patients with severe COPD and a history of hospitalisation Source: Eur Respir J, 50 (1) 1700158; 10.1183/13993003.00158-2017 Year: 2017
Effect of exacerbation history and ICS use on outcomes in COPD patients from the TIOSPIR™ trial Source: International Congress 2015 – New data on established treatments for COPD Year: 2015
Extrafine triple therapy in patients with symptomatic COPD and history of one moderate exacerbation Source: Eur Respir J, 53 (5) 1900235; 10.1183/13993003.00235-2019 Year: 2019
Physiological impairments and exacerbation risk in COPD patients with less symptom and no frequent exacerbation history. Source: Virtual Congress 2021 – Prediction of exacerbations in patients with COPD Year: 2021
Effect of roflumilast on exacerbations in patients with severe COPD and a prior history of hospitalization taking combination therapy Source: International Congress 2015 – Advances in the future treatment of COPD Year: 2015
Long-term effect of roflumilast on exacerbations in patients with severe to very severe COPD Source: Eur Respir J 2006; 28: Suppl. 50, 526s Year: 2006
Tiotropium improved asthma symptoms and increased time to first exacerbation in patients with moderate-to-severe asthma. Source: Virtual Congress 2020 – Asthma and cough: clinical trials and pharmacological insights Year: 2020
Effect of dupilumab on severe exacerbations in asthma patients with and without lung function improvements Source: Virtual Congress 2020 – Monoclonal antibodies; randomised controlled trials and real-world studies in asthma Year: 2020
Determinants of exacerbation rate in patients with stable COPD Source: Eur Respir J 2004; 24: Suppl. 48, 661s Year: 2004
β-blockers and risk of COPD exacerbation requiring hospitalisation in patients with COPD Source: Annual Congress 2011 - Biomarkers and exacerbations of asthma and COPD Year: 2011
COPD patients with asthma, characteristics and risk of exacerbations Source: International Congress 2019 – Multimorbidity in airway diseases and appropriate inhaled corticosteroid use in COPD Year: 2019
Add-on omalizumab therapy reduces clinically significant and severe asthma exacerbations, and improves FEV1 in patients with severe persistent allergic asthma irrespective of age Source: Eur Respir J 2005; 26: Suppl. 49, 48s Year: 2005
Influence of statin therapy on exacerbation frequency in patients with COPD Source: Annual Congress 2009 - Drug effects in COPD Year: 2009
Impact of roflumilast treatment on the rate and duration of exacerbations and overall steroid load in patients with COPD Source: Annual Congress 2011 - COPD management Year: 2011
Lack of effect of acute exacerbations on disease progression in ex-smoker COPD patients Source: Annual Congress 2010 - Distortions of the respiratory system in the lung function Year: 2010
Baseline characteristics of COPD patients with frequent COPD exacerbations in tiotropium trials Source: Eur Respir J 2006; 28: Suppl. 50, 175s Year: 2006
How frequent is bronchodilator reversibility in patients with stable asthma bronchiale and chronic obstructive lung disease (COPD) receiving maintenance therapy? Source: Annual Congress 2012 - Treatment of asthma, bronchiectasis and cough: inhaler use Year: 2012
Efficacy of roflumilast in the frequent exacerbation COPD phenotype Source: Annual Congress 2011 - Biomarkers and exacerbations of asthma and COPD Year: 2011
The effect of smoking on exacerbation risk in eosinophilic patients with COPD Source: Eur Respir J, 50 (6) 1701820; 10.1183/13993003.01820-2017 Year: 2017
The effect of smoking on exacerbation risk in eosinophilic patients with COPD Source: Eur Respir J, 50 (6) 1702086; 10.1183/13993003.02086-2017 Year: 2017